Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

19.07.2018 | original article | Ausgabe 17-18/2018

Wiener klinische Wochenschrift 17-18/2018

Austrian recommendations for the management of polycythemia vera

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 17-18/2018
Autoren:
Sonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, Christine Beham-Schmid, Günther Gastl, Klaus Geissler, Thomas Melchardt, Maria Krauth, Peter Krippl, Andreas Petzer, Holger Rumpold, Albert Wölfler, Heinz Gisslinger

Summary

Polycythemia vera (PV) is a clonal disease arising from hematopoietic stem cells. Erythrocytosis is the hallmark of the disease but leukocytosis, thrombocytosis and splenomegaly may also be present. Thromboembolic complications occur in about 20% of patients. Circulatory disturbances as well as pruritus represent frequent symptoms of the disease. Mutations in the JAK2 gene are present in 95% of patients in exon 14 (V617F) and in 3% in exon 12. The main goal of the treatment for patients with PV is the prevention of thromboembolic events, transformation to myelofibrosis and acute myeloid leukemia. Interferon alpha and hydroxyurea are used as first-line treatment for high risk patients. For patients unresponsive to first-line therapy ruxolitinib is available.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 17-18/2018

Wiener klinische Wochenschrift 17-18/2018 Zur Ausgabe

images in clinical medicine

Schatzki ring